

Wendel gives exclusivity to Ares Life Sciences to acquire its stake in Stallergenes.

Wendel received today a firm and irrevocable offer from Ares Life Sciences, an investment firm established by the Bertarelli family to invest in the healthcare industry, to acquire all of Wendel's equity interest in Stallergenes (46%). Wendel, through its subsidiary Oranje Nassau, and Ares Life Sciences have entered into an exclusivity period to finalise the transaction.

The transaction price would be €59 per share, meaning